Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 252 participants.

Also called NCT07064525

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 252 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07064525
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Enrolling by invitation (from the registry)

Technical summary

Registry record NCT07064525. Randomized; double masking; primary purpose treatment. Start 2024-12-05 (actual); primary completion 2025-12-15 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Condition
Hypertension (HTN)
Condition
NYHA Class III Heart Failure
Condition
NYHA Class IV Heart Failure
Condition
Diabete Mellitus
Intervention (Drug)
SPC1001 Low
Intervention (Drug)
SPC5002
Intervention (Drug)
SPC5003
Intervention (Drug)
SPC5004
Lead sponsor
Shin Poong Pharmaceutical Co. Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07064525
Content hash
430b00fffdf23304785ea4d4323aab25a6edc42fe19a25ea0a84a41bfd1b3650